Marex Group plc Buys Shares of 36,469 Arrowhead Pharmaceuticals, Inc. $ARWR

Marex Group plc purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 2nd quarter, HoldingsChannel reports. The firm purchased 36,469 shares of the biotechnology company’s stock, valued at approximately $576,000.

Other hedge funds also recently modified their holdings of the company. State of Wyoming bought a new position in Arrowhead Pharmaceuticals during the second quarter worth $142,000. Hudson Bay Capital Management LP grew its position in Arrowhead Pharmaceuticals by 22.0% in the 2nd quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company’s stock worth $4,108,000 after purchasing an additional 46,870 shares during the last quarter. Public Sector Pension Investment Board increased its holdings in shares of Arrowhead Pharmaceuticals by 7.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 428,386 shares of the biotechnology company’s stock worth $6,768,000 after purchasing an additional 28,516 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Arrowhead Pharmaceuticals by 107.3% during the second quarter. Tower Research Capital LLC TRC now owns 10,622 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 5,499 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $269,000. 62.61% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Mauro Ferrari sold 8,750 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $56.39, for a total transaction of $493,412.50. Following the completion of the sale, the director directly owned 68,764 shares of the company’s stock, valued at $3,877,601.96. This trade represents a 11.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. This represents a 8.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 45,000 shares of company stock worth $2,185,150. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ARWR shares. Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday. Piper Sandler boosted their price objective on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. The Goldman Sachs Group lifted their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research note on Thursday, November 20th. Finally, Chardan Capital restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $58.56.

Arrowhead Pharmaceuticals Trading Down 1.0%

Shares of Arrowhead Pharmaceuticals stock opened at $70.09 on Monday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $72.36. The stock has a market capitalization of $9.52 billion, a P/E ratio of -876.02 and a beta of 1.28. The company has a 50-day simple moving average of $45.48 and a 200 day simple moving average of $29.55. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.